Sign In

Login

Password

Forgot Password ? Sign Up

Certolizumab pegol (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Certolizumab pegol" in Vietnamese language version.

refsWebsite
Global rank Vietnamese rank
6nih.gov
4th place
7th place
5doi.org
2nd place
2nd place
3web.archive.org
1st place
1st place
2fda.gov
447th place
625th place
1landesbioscience.com
low place
low place
1ucb.com
low place
low place
1medscape.com
719th place
1,344th place
1europa.eu
68th place
114th place
1archive.today
14th place
27th place
1presscentre.com
low place
low place
1ucb-group.com
low place
low place
1city.ac.uk
low place
7,462nd place

archive.today

city.ac.uk

openaccess.city.ac.uk

doi.org

  • Sandborn WJ, Feagan BG, Stoinov S, và đồng nghiệp (tháng 7 năm 2007). “Certolizumab pegol for the treatment of Crohn's disease”. N. Engl. J. Med. 357 (3): 228–38. doi:10.1056/NEJMoa067594. PMC 3187683. PMID 17634458.
  • Goel, Niti; Sue Stephens (2010). “Certolizumab pegol”. mAbs. 2 (2): 137–147. doi:10.4161/mabs.2.2.11271. PMC 2840232. PMID 20190560.
  • Kaushik VV, Moots RJ (tháng 4 năm 2005). “CDP-870 (certolizumab) in rheumatoid arthritis”. Expert Opinion on Biological Therapy. 5 (4): 601–6. doi:10.1517/14712598.5.4.601. PMID 15934837.
  • Sieper J, Tubergen A, Coteur G, Woltering F, Landewe R (tháng 5 năm 2013). “PMS50 – Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study”. Value in Health. 16 (3): A227. doi:10.1016/j.jval.2013.03.1150.
  • Ruiz Garcia, V; Jobanputra, P; Burls, A; Vela Casasempere, P; Bort-Marti, S; Bernal, JA (8 tháng 9 năm 2017). “Certolizumab pegol (CDP870) for rheumatoid arthritis in adults” (PDF). The Cochrane Database of Systematic Reviews. 9: CD007649. doi:10.1002/14651858.CD007649.pub4. PMID 28884785.

europa.eu

emea.europa.eu

fda.gov

accessdata.fda.gov

landesbioscience.com

medscape.com

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Sandborn WJ, Feagan BG, Stoinov S, và đồng nghiệp (tháng 7 năm 2007). “Certolizumab pegol for the treatment of Crohn's disease”. N. Engl. J. Med. 357 (3): 228–38. doi:10.1056/NEJMoa067594. PMC 3187683. PMID 17634458.
  • Goel, Niti; Sue Stephens (2010). “Certolizumab pegol”. mAbs. 2 (2): 137–147. doi:10.4161/mabs.2.2.11271. PMC 2840232. PMID 20190560.
  • Kaushik VV, Moots RJ (tháng 4 năm 2005). “CDP-870 (certolizumab) in rheumatoid arthritis”. Expert Opinion on Biological Therapy. 5 (4): 601–6. doi:10.1517/14712598.5.4.601. PMID 15934837.
  • Ruiz Garcia, V; Jobanputra, P; Burls, A; Vela Casasempere, P; Bort-Marti, S; Bernal, JA (8 tháng 9 năm 2017). “Certolizumab pegol (CDP870) for rheumatoid arthritis in adults” (PDF). The Cochrane Database of Systematic Reviews. 9: CD007649. doi:10.1002/14651858.CD007649.pub4. PMID 28884785.

ncbi.nlm.nih.gov

  • Sandborn WJ, Feagan BG, Stoinov S, và đồng nghiệp (tháng 7 năm 2007). “Certolizumab pegol for the treatment of Crohn's disease”. N. Engl. J. Med. 357 (3): 228–38. doi:10.1056/NEJMoa067594. PMC 3187683. PMID 17634458.
  • Goel, Niti; Sue Stephens (2010). “Certolizumab pegol”. mAbs. 2 (2): 137–147. doi:10.4161/mabs.2.2.11271. PMC 2840232. PMID 20190560.

presscentre.com

ucb.presscentre.com

ucb-group.com

ir.ucb-group.com

ucb.com

web.archive.org